Interaction Between Gut Microbiota and TKIs in Defining the Clinical Outcomes of Patients With CML
Interaction Between Gut Microbiota and TKIs in Defining the Clinical Outcomes of Patients With CML
Recruiting · NCT06724536 · Registry updated 2024-12-09Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Interaction Between Gut Microbiota and TKIs in Defining the Clinical Outcomes of Patients With CML | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Not stated | 2024-12-09 | NCT06724536 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Carmen Fava | 2 |
| Novartis | 114 |
| Pfizer | 431 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Ao Ordine Mauriziano Di Torino | Torino | Italy | 3 |